IMMUNEERING CORP - CLASS A (IMRX) Stock Overview
USA - NASDAQ:IMRX - US45254E1073 - Common Stock
IMRX Key Statistics, Chart & Performance
The current stock price of IMRX is 5.8 USD. In the past month the price decreased by -35.74%. In the past year, price increased by 179.1%.
IMRX Latest News, Press Relases and Analysis
IMRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.82 | 408.16B | ||
| AMGN | AMGEN INC | 13.83 | 162.34B | ||
| GILD | GILEAD SCIENCES INC | 15.9 | 152.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.11 | 109.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.07B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.23B | ||
| ARGX | ARGENX SE - ADR | 91.35 | 51.80B | ||
| INSM | INSMED INC | N/A | 34.53B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.12 | 34.83B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.72B | ||
| NTRA | NATERA INC | N/A | 25.75B | ||
| BIIB | BIOGEN INC | 9.15 | 21.48B |
Related stock screener links
About IMRX
Company Profile
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Company Info
IMMUNEERING CORP - CLASS A
245 Main Street, Second Floor
Cambridge MASSACHUSETTS US
CEO: Benjamin J. Zeskind
Employees: 66
Phone: 16175008080
IMMUNEERING CORP - CLASS A / IMRX FAQ
What is the stock price of IMMUNEERING CORP - CLASS A today?
The current stock price of IMRX is 5.8 USD. The price increased by 3.39% in the last trading session.
What is the ticker symbol for IMMUNEERING CORP - CLASS A stock?
The exchange symbol of IMMUNEERING CORP - CLASS A is IMRX and it is listed on the Nasdaq exchange.
On which exchange is IMRX stock listed?
IMRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUNEERING CORP - CLASS A stock?
11 analysts have analysed IMRX and the average price target is 16.93 USD. This implies a price increase of 191.93% is expected in the next year compared to the current price of 5.8. Check the IMMUNEERING CORP - CLASS A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUNEERING CORP - CLASS A worth?
IMMUNEERING CORP - CLASS A (IMRX) has a market capitalization of 334.43M USD. This makes IMRX a Small Cap stock.
How many employees does IMMUNEERING CORP - CLASS A have?
IMMUNEERING CORP - CLASS A (IMRX) currently has 66 employees.
What are the support and resistance levels for IMMUNEERING CORP - CLASS A (IMRX) stock?
IMMUNEERING CORP - CLASS A (IMRX) has a support level at 5.57. Check the full technical report for a detailed analysis of IMRX support and resistance levels.
Should I buy IMMUNEERING CORP - CLASS A (IMRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMRX, evaluating the profitability, health, valuation and growth aspects
- IMMUNEERING CORP - CLASS A (IMRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUNEERING CORP - CLASS A (IMRX) Sales and EPS estimates to see what analysts future expectations are.
- IMMUNEERING CORP - CLASS A (IMRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUNEERING CORP - CLASS A (IMRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUNEERING CORP - CLASS A (IMRX) Stock Chart to make your own analysis
- IMMUNEERING CORP - CLASS A (IMRX) Latest news and press-releases to stay up to date.
Does IMMUNEERING CORP - CLASS A (IMRX) stock pay dividends?
IMRX does not pay a dividend.
When does IMMUNEERING CORP - CLASS A (IMRX) report earnings?
IMMUNEERING CORP - CLASS A (IMRX) will report earnings on 2025-11-06, after the market close.
What is the Price/Earnings (PE) ratio of IMMUNEERING CORP - CLASS A (IMRX)?
IMMUNEERING CORP - CLASS A (IMRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.89).
What is the Short Interest ratio of IMMUNEERING CORP - CLASS A (IMRX) stock?
The outstanding short interest for IMMUNEERING CORP - CLASS A (IMRX) is 9.02% of its float. Check the ownership tab for more information on the IMRX short interest.
IMRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to IMRX. When comparing the yearly performance of all stocks, IMRX is one of the better performing stocks in the market, outperforming 96.51% of all stocks.
IMRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMRX. IMRX has a great financial health rating, but its profitability evaluates not so good.
IMRX Financial Highlights
Over the last trailing twelve months IMRX reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS increased by 1.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -121.73% | ||
| ROE | -147.44% | ||
| Debt/Equity | 0 |
IMRX Forecast & Estimates
11 analysts have analysed IMRX and the average price target is 16.93 USD. This implies a price increase of 191.93% is expected in the next year compared to the current price of 5.8.